<p>The Overexpression of Kinesin Superfamily Protein 2A (KIF2A) was Associated with the Proliferation and Prognosis of Esophageal Squamous Cell Carcinoma</p>
Authors: Demao Li
Linglei Meng
Huijie Sun
Deshang Li
Journal: Cancer Management and Research (2020)
Discipline: CLINICAL MEDICINE
Keywords: ESCC; KIF2A; esophageal squamous cell carcinoma; kinesin superfamily protein 2A; proliferation.
Affiliations: Department of Thoracic Surgery, Xingtai People's Hospital, Xingtai City, Hebei 054000, People's Republic of China., Department of Pharmacy, Xingtai Medical College, Xingtai City, Hebei 054000, People's Republic of China., Department of CT/MR, Xingtai People's Hospital, Xingtai City, Hebei 054000, People's Republic of China., Department of Laboratory, Xingtai People's Hospital, Xingtai City, Hebei 054000, People's Republic of China.

Abstract:  Aim: Kinesin family member 2A (KIF2A) is a member of the kinesin-13 superfamily protein. KIF2A played a role in the development of many tumors. However, the role of KIF2A in esophageal squamous cell carcinoma (ESCC) remains unclear. In this study, we aimed to investigate the role of KIF2A in ESCC. Methods: We used bioinformatics analysis to study the expression levels and prognosis of KIF2A in ESCC and normal tissues. We also used our own samples to verify the results by immunohistochemistry. Then, the biological functions of KIF2A in ESCC was studied by cell experiments and animal experiments. Results: Both the TCGA database and our samples showed that KIF2A was relatively highly expressed in ESCC tissues and was significantly associated with disease-free survival (P =0.037) in TCGA database. Colony formation assay, CCK8 and Western blotting results showed that knockdown of KIF2A can significantly reduce colony forming ability and proliferation ability. The results of animal experiments showed that knocking down KIF2A can significantly reduce the tumor volume of mice. Conclusion: KIF2A might be used as a prognostic factor for ESCC, and knockdown of KIF2A could inhibit ESCC proliferation in vitro and in vivo, respectively. KIF2A could serve as a potential prognostic biomarker and therapeutic target for future ESCC. 

Retracted: Yes

PubPeer comments:
 Retracted, [3 March 2022] . ------------------- The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised following a request from the authors to replace in vivo and immunohistochemistry (IHC) images in Figure 4 due to the authors having lost the original data and being unable to verify the findings as reported. The authors could not provide a satisfactory explanation for how their repeated experiments supported the original findings, given the original data was no longer available. In addition, the animal ethics approval documents provided by the authors for the original study were not satisfactory. The findings of the article were deemed unreliable, and the Editor requested for the article to be retracted. Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as u201cRetractedu201d. ------------------------- There seem to be additional problems. Fig 2B, for instance ( KIF2A knocking down cells for CaEs-17 and EC-109 cell lines ): the CaEs-17 and EC-109 WBs are the same, apart from a vertical stretch. ![file] ,